Literature DB >> 17127170

Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.

Toshihiko Hara1, Aditya Bansal, Timothy R DeGrado.   

Abstract

INTRODUCTION: Choline, acetate and glucose ([2-(18)F]fluoro-2-deoxyglucose, [(18)F]FDG) analogs are under investigation as positron emission tomography (PET) tracers for the imaging of prostate cancer; however, their response to tumor hypoxia has not been clarified.
METHODS: The uptake of [methyl-(3)H]choline, [1-(14)C]acetate and [(18)F]FDG was monitored in androgen-independent PC-3 cells and androgen-sensitive LNCaP cells under aerobic or anoxic conditions. The effect of androgen depletion was also examined.
RESULTS: PC-3 cells exhibited aerobic choline and acetate uptake five to six times higher than FDG uptake, whereas LNCaP cells showed choline uptake 2.2-fold higher than acetate uptake and 10-fold higher than FDG uptake. After 4 h of anoxia, PC-3 cells showed an 85% increase in FDG uptake, a 15% decrease in choline uptake and a 36% increase in acetate uptake, whereas LNCaP cells showed a 212% increase in FDG uptake, a 28% decrease in choline uptake and no change in acetate uptake. Androgen depletion resulted in a marked decrease in the uptake of all tracers in LNCaP cells but no changes in PC-3 cells.
CONCLUSION: In aerobic conditions, both PC-3 and LNCaP cells exhibited an order of uptake preference as follows: choline>acetate>FDG. In hypoxic cells, the order is reversed, reflecting diverse biochemical responses to hypoxia. These findings may help to explain PET imaging findings of the diverse responses of these tracers in different stages and locations of prostate cancer. Androgen depletion markedly suppressed the uptake of all three tracers in LNCaP cells, which suggests the potential for underestimation of the disease state when PET imaging is performed subsequent to antiandrogen therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127170     DOI: 10.1016/j.nucmedbio.2006.08.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  39 in total

1.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

2.  Hypoxia activates constitutive luciferase reporter constructs.

Authors:  Diane M Doran; Kashmira Kulkarni-Datar; David R Cool; Thomas L Brown
Journal:  Biochimie       Date:  2010-10-26       Impact factor: 4.079

3.  High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.

Authors:  Xiao-Feng Li; Yuanyuan Ma; Xiaorong Sun; John L Humm; C Clifton Ling; Joseph A O'Donoghue
Journal:  J Nucl Med       Date:  2010-04       Impact factor: 10.057

4.  Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?

Authors:  Giampiero Giovacchini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11       Impact factor: 9.236

5.  Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?

Authors:  Kimy M Emonds; Johannes V Swinnen; Wytske M van Weerden; Frank Vanderhoydonc; Johan Nuyts; Luc Mortelmans; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 6.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

7.  Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer.

Authors:  Rutger J Dost; Andor W J M Glaudemans; Anthonius J Breeuwsma; Igle J de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

8.  [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.

Authors:  Giampiero Giovacchini; Maria Picchio; Elisa Coradeschi; Vincenzo Scattoni; Valentino Bettinardi; Cesare Cozzarini; Massimo Freschi; Ferruccio Fazio; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-16       Impact factor: 9.236

Review 9.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

10.  Characterization of preclinical models of prostate cancer using PET-based molecular imaging.

Authors:  Sara Belloli; Elena Jachetti; Rosa M Moresco; Maria Picchio; Michela Lecchi; Silvia Valtorta; Massimo Freschi; Rodrigo Hess Michelini; Matteo Bellone; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.